Cargando…
Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict
BACKGROUND: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic therapy and require treatment intensification. Intensification decisions can be difficult because of many available options and their many benefits and risks. The American Diabetes Associati...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712511/ https://www.ncbi.nlm.nih.gov/pubmed/26762150 http://dx.doi.org/10.1186/s12913-016-1262-4 |
_version_ | 1782410078078369792 |
---|---|
author | Bailey, Robert. A. Pfeifer, Michael Shillington, Alicia C. Harshaw, Qing Funnell, Martha M. VanWingen, Jeffrey Col, Nanada |
author_facet | Bailey, Robert. A. Pfeifer, Michael Shillington, Alicia C. Harshaw, Qing Funnell, Martha M. VanWingen, Jeffrey Col, Nanada |
author_sort | Bailey, Robert. A. |
collection | PubMed |
description | BACKGROUND: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic therapy and require treatment intensification. Intensification decisions can be difficult because of many available options and their many benefits and risks. The American Diabetes Association recommends patient-centered, evidence-based tools supporting shared decision-making between patients and clinicians. We developed a patient decision aid (PDA) targeting decisions about treatment intensification for T2DM. Our objective was to determine the effectiveness of this PDA for patients with T2DM on metformin who require treatment intensification. METHODS: This study was a pragmatic randomized controlled trial conducted in 27 US primary care and endocrinology clinics. Subjects were English-speaking adults with T2DM receiving metformin with persistent hyperglycemia who were recommended to consider medication intensification. Subjects were randomized to receive either the PDA or usual care (UC). Main outcome measures were change in knowledge, decisional self-efficacy, and decisional conflict. RESULTS: Of 225 subjects enrolled, 114 were randomized to the PDA and 111 to UC. Mean [SD] age was 52 [1] years, time since T2DM diagnosis was 6 [+/−6] years, 45.3 % were male, and most (55.5 %) were non-Caucasian. Compared to UC, PDA users had significantly larger knowledge gains (35.0 % [22.3] vs 9.9 % [22.2]; P < 0.0001) and larger improvements in self-efficacy (3.7 [16.7] vs−3.9 [19.2]; P < 0.0001) and decisional conflict (−22.2 [20.6] vs−7.5 [16.6]; P < 0.0001). CONCLUSIONS: The PDA resulted in substantial and significant improvements in knowledge, decisional conflict and decisional self-efficacy. Decisional conflict scores after PDA use were within the range that correlates with effective decision-making. This PDA has the potential to facilitate shared-decision-making for patients with T2DM. TRIAL REGISTRATION: NCT02110979 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-016-1262-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4712511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47125112016-01-15 Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict Bailey, Robert. A. Pfeifer, Michael Shillington, Alicia C. Harshaw, Qing Funnell, Martha M. VanWingen, Jeffrey Col, Nanada BMC Health Serv Res Research Article BACKGROUND: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic therapy and require treatment intensification. Intensification decisions can be difficult because of many available options and their many benefits and risks. The American Diabetes Association recommends patient-centered, evidence-based tools supporting shared decision-making between patients and clinicians. We developed a patient decision aid (PDA) targeting decisions about treatment intensification for T2DM. Our objective was to determine the effectiveness of this PDA for patients with T2DM on metformin who require treatment intensification. METHODS: This study was a pragmatic randomized controlled trial conducted in 27 US primary care and endocrinology clinics. Subjects were English-speaking adults with T2DM receiving metformin with persistent hyperglycemia who were recommended to consider medication intensification. Subjects were randomized to receive either the PDA or usual care (UC). Main outcome measures were change in knowledge, decisional self-efficacy, and decisional conflict. RESULTS: Of 225 subjects enrolled, 114 were randomized to the PDA and 111 to UC. Mean [SD] age was 52 [1] years, time since T2DM diagnosis was 6 [+/−6] years, 45.3 % were male, and most (55.5 %) were non-Caucasian. Compared to UC, PDA users had significantly larger knowledge gains (35.0 % [22.3] vs 9.9 % [22.2]; P < 0.0001) and larger improvements in self-efficacy (3.7 [16.7] vs−3.9 [19.2]; P < 0.0001) and decisional conflict (−22.2 [20.6] vs−7.5 [16.6]; P < 0.0001). CONCLUSIONS: The PDA resulted in substantial and significant improvements in knowledge, decisional conflict and decisional self-efficacy. Decisional conflict scores after PDA use were within the range that correlates with effective decision-making. This PDA has the potential to facilitate shared-decision-making for patients with T2DM. TRIAL REGISTRATION: NCT02110979 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-016-1262-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-14 /pmc/articles/PMC4712511/ /pubmed/26762150 http://dx.doi.org/10.1186/s12913-016-1262-4 Text en © Bailey et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bailey, Robert. A. Pfeifer, Michael Shillington, Alicia C. Harshaw, Qing Funnell, Martha M. VanWingen, Jeffrey Col, Nanada Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict |
title | Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict |
title_full | Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict |
title_fullStr | Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict |
title_full_unstemmed | Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict |
title_short | Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict |
title_sort | effect of a patient decision aid (pda) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712511/ https://www.ncbi.nlm.nih.gov/pubmed/26762150 http://dx.doi.org/10.1186/s12913-016-1262-4 |
work_keys_str_mv | AT baileyroberta effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict AT pfeifermichael effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict AT shillingtonaliciac effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict AT harshawqing effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict AT funnellmartham effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict AT vanwingenjeffrey effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict AT colnanada effectofapatientdecisionaidpdafortype2diabetesonknowledgedecisionalselfefficacyanddecisionalconflict |